sodium fluoride (18F)
Approved
Feb 24, 1972
FLUORIDE ION F-18 (as sodium fluoride F-18) is a radioactive diagnostic agent for positron emission tomography (PET) indicated for imaging of bone to define areas of altered osteogenic activity. FLUORIDE ION F-18 normally accumulates in the skeleton in an even fashion, with greater deposition in the axial skeleton (e.g. vertebrae and pelvis) than in the appendicular skeleton and greater deposition in the bones around joints than in the shafts of long bones. Increased FLUORIDE ION F-18 deposition in the bone can occur in areas of increased osteogenic activity during growth, infection, malignancy (primary or metastatic) following trauma, or inflammation of the bone. — NCATS
Clinical trial activity
291 trials · 182 clinical orgs · 30 marketing orgs
Earliest trial started Nov 1, 1998 (NCT00018447)
Timeline
1970s
- Feb 24, 1972
General Electric — Earliest FDA Approval
- Feb 24, 1972
General Electric — NDA Secondary Org
- Feb 24, 1972
General Electric — NDA Organization
1990s
- Jul 11, 1997
Colgate Palmolive — NDA Secondary Org
- Jan 1, 1998
Earliest Phase 2 Sponsor(trial)
2000s
- Jan 1, 2000
Colgate Palmolive — Earliest Phase 3 Sponsor(trial)
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
2010s
- Jan 26, 2011
National Institutes of Health (NIH) — NDA Secondary Org
- Dec 26, 2012
Houston Cyclotron — Marketing Organization
- Jun 28, 2013
University of Pennsylvania — Marketing Organization
- Dec 23, 2013
University of Texas at Houston — Marketing Organization
- Mar 13, 2014
University of California, San Francisco — Marketing Organization
- Sep 22, 2014
Shertech Labs Llc — Marketing Organization
- Oct 21, 2014
Zevacor — Marketing Organization
- Oct 21, 2014
Decatur Memorial Hospital — Marketing Organization
- Oct 29, 2014
Essential Isotopes, LLC — Marketing Organization
- Nov 19, 2014
Feinstein Institute for Medical Research — Marketing Organization
- Nov 28, 2014
NCM USA — Marketing Organization
- Jan 9, 2015
Biomedical Research Foundation — Marketing Organization
- Feb 27, 2015
Precision Nuclear — Marketing Organization
- Apr 20, 2015
University of Utah — Marketing Organization
- Apr 22, 2015
Spectron Mrc Llc — Marketing Organization
- Apr 22, 2015
Nukemed — Marketing Organization
- Jul 21, 2015
Stanford University — Marketing Organization
- Jul 29, 2015
Hot Shots Nuclear Medicine — Marketing Organization
- Jul 30, 2015
Cardinal Health — Marketing Organization
- Aug 18, 2015
Sofie — Marketing Organization
- Sep 28, 2015
Siemens — Marketing Organization
- Oct 19, 2015
3d Imaging Drug Design & Development — Marketing Organization
- Oct 23, 2015
Jubilant DraxImage Inc. — Marketing Organization
- Oct 23, 2015
Jubilant Innovation Ltd. — Marketing Organization
- Nov 17, 2015
Midwest Medical Isotopes — Marketing Organization
- Nov 17, 2015
University of Iowa — Marketing Organization
- May 19, 2016
Columbia University — Marketing Organization
2020s
- Dec 6, 2022
BAMF Health — Marketing Organization
Indications
Studied for
- Acne Vulgaris · Phase 3
- Adult · Phase 3
- Allergy and Immunology · Phase 2/Phase 3
- Aortic Valve Stenosis · Phase 2
- Bacterial Infections · Phase 3
- Breast Neoplasms · Phase 3
- Cariostatic Agents · Phase 4
- Carotid Stenosis · Phase 2
- Chronic Periodontitis · Phase 3
- Coronary Artery Disease · Phase 4
- Coronavirus Infections · Phase 2
- COVID-19 · Phase 2
- Dental Caries · Phase 4
- Dental Caries Susceptibility · Phase 4
- Dental Enamel · Phase 3
- Dental Enamel Hypoplasia · Phase 3
- Dental Plaque · Phase 4
- Dentin Desensitizing Agents · Phase 2/Phase 3
- Dentin Sensitivity · Phase 4
- Denture, Partial · Phase 3
- Dermatology · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Down Syndrome · Phase 2
- Fluorides, Topical · Phase 4
- Fluorosis, Dental · Phase 4
- General Surgery · Phase 4
- Gingival Diseases · Phase 3
- Gingivitis · Phase 4
- Healthy Volunteers · Phase 3
- Hypersensitivity · Phase 2/Phase 3
- Infections · Phase 3
- Minerals · Phase 3
- Monoclonal Gammopathy of Undetermined Significance · Phase 2
- Mouth · Phase 4
- Mucositis · Phase 3
- Multiple Myeloma · Phase 2
- Neoplasm Metastasis · Phase 3
- Neoplasms · Phase 4
- Oral Hygiene · Phase 4
- Orthodontic Appliances, Fixed · Phase 2
- Osteoporosis, Postmenopausal · Phase 2
- Peri-Implantitis · Phase 3
- Periodontal Diseases · Phase 4
- Periodontitis · Phase 3
- Plaque, Atherosclerotic · Phase 4
- Prostatic Neoplasms · Phase 2
- Root Caries · Phase 1
- Saliva · Phase 3
- Smoldering Multiple Myeloma · Phase 2
- Sodium Fluoride · Phase 2
- Stomatognathic Diseases · Early Phase 1
- Tooth · Phase 1/Phase 2
- Tooth Abnormalities · Phase 4
- Tooth Demineralization · Phase 4
- Tooth Erosion · Phase 3
- Xerostomia · Phase 1
Mechanism of action
- BoneBINDING AGENT
Bone binding agent
Combination products
colgate total
with triclosan
Approval history
- approvedFeb 24, 1972
Chemistry & pharmacology
SMILES
[F-].[Na+]- Mol. weight
- 41.99 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
- Imaging
- 18-fluorine
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL1528 ↗
- WikipediaFluoride ↗
- NCATS4M4WE5N2GE ↗
- ChEMBLCHEMBL1232767 ↗
- ChEMBLCHEMBL1200744 ↗
- WikipediaSodium fluoride ↗
- NCATSQ80VPU408O ↗
- WikipediaCalcium fluoride ↗
- ChEMBLCHEMBL1362 ↗
- ChEMBLCHEMBL1248 ↗
Also known as
- 18f
- 18f-fluoride
- 18f naf
- 18f naf
- 18f-naf
- 18f-naf
- 18f-sodium fluoride
- 18-naf
- calcium fluoride
- calcium fluoride
- dentiplus
- durafluor
- duraphat
- duraphat
- duraphat
- en-de-kay
- fluor-a-day
- fluoride
- fluoride
- fluoride ion f-18
- fluorigard
- fluorigard
- fluorigard daily
- fluorigard weekly
- fluorine-18
- fluorine-18
- fluorine f-18
- fluorine f-18
- fluorinse
- fluorinse
- fluor ret
- minute-gel
- minute-gel
- nafril ret
- neutra care
- neutra care
- ossin
- ossin
- osteofluor
- osteofluor
- pediaflor
- pediaflor
- point-two
- point-two
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride
- sodium fluoride (18f)
- sodium fluoride (18f)
- sodium fluoride (18f)
- sodium fluoride-18f
- sodium fluoride (f18)
- sodium fluoride (f18)
- sodium fluoride f 18
- sodium fluoride f 18
- sodium fluoride f-18
- sodium fluoride f-18
- sodium fluoride f-18
- sodium fluoride f-18
- sodium fluoride f 18 injection
- sodium fluoride topical preparation
- sodium monofluoride
- thera-flur
- zymafluor
- zymafluor
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07225478 | Phase 3 | Oct 31, 2025 | Colgate Palmolive |
| NCT07273539 | N/A | Oct 27, 2025 | Healeon Medical Inc, University of Birmingham |
| NCT07134231 | Phase 3 | Oct 9, 2025 | Colgate Palmolive, Federal University of Alagoas |
| NCT06932926 | Phase 2 | Sep 30, 2025 | Cairo University |
| NCT07181967 | N/A | Sep 15, 2025 | Assiut University |
| NCT07065305 | Early Phase 1 (Phase 1) | Sep 15, 2025 | Al Azhar University, Misr University for Science and Technology |
| NCT07284563 | Phase 2 | Sep 1, 2025 | — |
| NCT07141576 | N/A | Sep 1, 2025 | Cairo University |
| NCT06961604 | Early Phase 1 (Phase 1) | Jun 1, 2025 | Atlantic Health System |
| NCT06902532 | N/A | May 1, 2025 | Cairo University |
| NCT07113847 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2025 | British University In Egypt |
| NCT06892834 | Phase 2 | Mar 25, 2025 | All Sum Research Center Ltd., Procter and Gamble |
| NCT07063433 | N/A | Feb 1, 2025 | British University In Egypt |
| NCT06797882 | Phase 2 | Jan 31, 2025 | National University of Malaysia |
| NCT06732518 | Phase 3 | Jan 30, 2025 | Colgate Palmolive, Federal University of Alagoas |
| NCT06821724 | N/A | Dec 1, 2024 | National Research Center, Egypt |
| NCT06829277 | N/A | Nov 1, 2024 | MTI University |
| NCT07229105 | N/A | Aug 12, 2024 | Bezmialem University |
| NCT06837779 | N/A | Jul 1, 2024 | Al Azhar University |
| NCT06430060 | Phase 3 | Jun 30, 2024 | Colgate Palmolive |
Organizations
Research & Development (182)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Colgate Palmolive | For profit | 48 | 42 | 5 | 2000 |
| GlaxoSmithKline | For profit | 33 | 32 | 5 | 2007 |
| Cairo University | Academic/Hospital | 26 | 26 | 5 | 2017 |
| National Cancer Institute (NCI) | Government | 10 | 6 | 3 | 2009 |
| Procter and Gamble | For profit | 9 | 9 | 5 | 2012 |
| The University of Hong Kong | Academic/Hospital | 8 | 8 | 3 | 2006 |
| Alexandria University | Academic/Hospital | 5 | 5 | 4 | 2018 |
| Al Azhar University | Academic/Hospital | 4 | 4 | 3 | 2019 |
| Federal University of Paraiba | Academic/Hospital | 4 | 2 | 3 | 2006 |
| Johnson and Johnson | For profit | 4 | 4 | 1 | 2009 |
| King Abdul-Aziz University | Academic/Hospital | 4 | 4 | 2 | 2009 |
| University of California, San Francisco | Academic/Hospital | 4 | 4 | 3 | 2003 |
| University of Texas, San Antonio | Academic/Hospital | 4 | 2 | 3 | 2012 |
| University of Washington | Academic/Hospital | 4 | 2 | 3 | 2003 |
| Healeon Medical Inc | For profit | 3 | 3 | 1 | 2022 |
| Indiana University | Academic/Hospital | 3 | 2 | 2 | 2012 |
| Mansoura University | Academic/Hospital | 3 | 3 | 2 | 2020 |
| National Institute of Dental and Craniofacial Research (NIDCR) | Government | 3 | 0 | 2 | 2001 |
| Rowpar Pharmaceuticals, Inc. | For profit | 3 | 3 | 2 | 2016 |
| Stanford University | Academic/Hospital | 3 | 3 | 3 | 2006 |
Marketing (31)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| 3d Imaging Drug Design & Development | For profit | MKTG | Oct 19, 2015 |
| BAMF Health | For profit | MKTG | Dec 6, 2022 |
| Biomedical Research Foundation | Academic/Hospital | MKTG | Jan 9, 2015 |
| Cardinal Health | Academic/Hospital | MKTG | Jul 30, 2015 |
| Colgate Palmolive | For profit | NDA2 | Jul 11, 1997 |
| Columbia University | Academic/Hospital | MKTG | May 19, 2016 |
| Decatur Memorial Hospital | Academic/Hospital | MKTG | Oct 21, 2014 |
| Essential Isotopes, LLC | For profit | MKTG | Oct 29, 2014 |
| Feinstein Institute for Medical Research | Academic/Hospital | MKTG | Nov 19, 2014 |
| General Electric | For profit | NDA2 | Feb 24, 1972 |
| General Electric | For profit | NDA | Feb 24, 1972 |
| Hot Shots Nuclear Medicine | For profit | MKTG | Jul 29, 2015 |
| Houston Cyclotron | For profit | MKTG | Dec 26, 2012 |
| Jubilant DraxImage Inc. | For profit | MKTG | Oct 23, 2015 |
| Jubilant Innovation Ltd. | For profit | MKTG | Oct 23, 2015 |
| Midwest Medical Isotopes | For profit | MKTG | Nov 17, 2015 |
| NCM USA | For profit | MKTG | Nov 28, 2014 |
| National Institutes of Health (NIH) | Government | NDA2 | Jan 26, 2011 |
| Nukemed | For profit | MKTG | Apr 22, 2015 |
| Precision Nuclear | For profit | MKTG | Feb 27, 2015 |
| Shertech Labs Llc | For profit | MKTG | Sep 22, 2014 |
| Siemens | For profit | MKTG | Sep 28, 2015 |
| Sofie | For profit | MKTG | Aug 18, 2015 |
| Spectron Mrc Llc | For profit | MKTG | Apr 22, 2015 |
| Stanford University | Academic/Hospital | MKTG | Jul 21, 2015 |
| University of California, San Francisco | Academic/Hospital | MKTG | Mar 13, 2014 |
| University of Iowa | Academic/Hospital | MKTG | Nov 17, 2015 |
| University of Pennsylvania | Academic/Hospital | MKTG | Jun 28, 2013 |
| University of Texas at Houston | Academic/Hospital | MKTG | Dec 23, 2013 |
| University of Utah | Academic/Hospital | MKTG | Apr 20, 2015 |
| Zevacor | For profit | MKTG | Oct 21, 2014 |